1. |
Bernell O, Lapidus A, Hellers G. Risk factors for surgery and postoperative recurrence in Crohn’s disease. Ann Surg, 2000, 231(1): 38-45.
|
2. |
de Groof EJ, Rossen NG, van Rhijn BD, et al. Burden of disease and increasing prevalence of inflammatory bowel disease in a population-based cohort in the Netherlands. Eur J Gastroenterol Hepatol, 2016, 28(9): 1065-1072.
|
3. |
Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol, 2005, 19(Suppl A): 5A-36A.
|
4. |
Subramanian S, Ekbom A, Rhodes JM. Recent advances in clinical practice: a systematic review of isolated colonic Crohn’s disease: the third IBD? Gut, 2017, 66(2): 362-381.
|
5. |
Gomollón F, Dignass A, Annese V, et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: part 1: diagnosis and medical management. J Crohns Colitis, 2017, 11(1): 3-25.
|
6. |
Zisman TL, Cohen RD. Pharmacoeconomics and quality of life of current and emerging biologic therapies for inflammatory bowel disease. Curr Treat Options Gastroenterol, 2007, 10(3): 185-194.
|
7. |
Crohn BBGL, Oppenheimer GD. Regional ileitis. A pathologic and clinical entity. J Am Med Assoc, 1932, 99: 1323-1329.
|
8. |
Lockhart-mummery HE, Morson BC. Crohn’s disease (regional enteritis) of the large intestine and its distinction from ulcerative colitis. Gut, 1960, 1: 87-105.
|
9. |
Cleynen I, Boucher G, Jostins L, et al. Inherited determinants of Crohn’s disease and ulcerative colitis phenotypes: a genetic association study. Lancet, 2016, 387(10014): 156-167.
|
10. |
中华医学会病理学分会消化病理学组筹备组, 中华医学会消化病学分会炎症性肠病学组. 中国炎症性肠病组织病理诊断共识意见. 中华病理学杂志, 2014, 43(4): 268-274.
|
11. |
Ponsioen CY, de Groof EJ, Eshuis EJ, et al. Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn’s disease: a randomised controlled, open-label, multicentre trial. Lancet Gastroenterol Hepatol, 2017, 2(11): 785-792.
|
12. |
de Groof EJ, Stevens TW, Eshuis EJ, et al. Cost-effectiveness of laparoscopic ileocaecal resection versus infliximab treatment of terminal ileitis in Crohn’s disease: the LIR!C Trial. Gut, 2019, 68(10): 1774-1780.
|
13. |
Eshuis EJ, Peters CP, van Bodegraven AA, et al. Ten years of infliximab for Crohn’s disease: outcome in 469 patients from2 tertiary referral centers. Inflamm Bowel Dis, 2013, 19(8): 1622-1630.
|
14. |
Gionchetti P, Dignass A, Danese S, et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: part 2: surgical management and special situations. J Crohns Colitis, 2017, 11(2): 135-149.
|
15. |
Picco MF, Zubiaurre I, Adluni M, et al. Immunomodulators are associated with a lower risk of first surgery among patients with non-penetrating non-stricturing Crohn’s disease. Am J Gastroenterol, 2009, 104(11): 2754-2759.
|
16. |
Harper PH, Truelove SC, Lee EC, et al. Split ileostomy and ileocolostomy for Crohn’s disease of the colon and ulcerative colitis: a 20 year survey. Gut, 1983, 24(2): 106-113.
|
17. |
Harb WJ. Crohn’s disease of the colon, rectum, and anus. Surg Clin North Am, 2015, 95(6): 1195-1210.
|
18. |
Sandborn WJ, Fazio VW, Feagan BG, et al. AGA technical review on perianal Crohn’s disease. Gastroenterology, 2003, 125(5): 1508-1530.
|
19. |
Beaugerie L, Seksik P, Nion-Larmurier I, et al. Predictors of Crohn’s disease. Gastroenterology, 2006, 130(3): 650-656.
|
20. |
Lapidus A, Bernell O, Hellers G, et al. Clinical course of colorectal Crohn’s disease: a 35-year follow-up study of 507 patients. Gastroenterology, 1998, 114(6): 1151-1160.
|
21. |
Tarrant KM, Barclay ML, Frampton CM, et al. Perianal disease predicts changes in Crohn’s disease phenotype-results of a population-based study of inflammatory bowel disease phenotype. Am J Gastroenterol, 2008, 103(12): 3082-3093.
|
22. |
Ruffolo C, Citton M, Scarpa M, et al. Perianal Crohn’s disease: is there something new? World J Gastroenterol, 2011, 17(15): 1939-1946.
|
23. |
Maser EA, Sachar DB, Kruse D, et al. High rates of metachronous colon cancer or dysplasia after segmental resection or subtotal colectomy in Crohn’s colitis. Inflamm Bowel Dis, 2013, 19(9): 1827-1832.
|
24. |
Dignass A, Van Assche G, Lindsay JO, et al. The second European evidence-based consensus on the diagnosis and management of Crohn’s disease: current management. J Crohns Colitis, 2010, 4(1): 28-62.
|
25. |
Prudhomme M, Dehni N, Dozois RR, et al. Causes and outcomes of pouch excision after restorative proctocolectomy. Br J Surg, 2006, 93(1): 82-86.
|
26. |
Brown CJ, Maclean AR, Cohen Z, et al. Crohn’s disease and indeterminate colitis and the ileal pouch-anal anastomosis: outcomes and patterns of failure. Dis Colon Rectum, 2005, 48(8): 1542-1549.
|
27. |
Marchal L, D’Haens G, Van Assche G, et al. The risk of post-operative complications associated with infliximab therapy for Crohn’s disease: a controlled cohort study. Aliment Pharmacol Ther, 2004, 19(7): 749-754.
|
28. |
Fichera A, Michelassi F. Surgical treatment of Crohn’s disease. J Gastrointest Surg, 2007, 11(6): 791-803.
|
29. |
Regimbeau JM, Panis Y, Pocard M, et al. Long-term results of ileal pouch-anal anastomosis for colorectal Crohn’s disease. Dis Colon Rectum, 2001, 44(6): 769-778.
|
30. |
Reese GE, Lovegrove RE, Tilney HS, et al. The effect of Crohn’s disease on outcomes after restorative proctocolectomy. Dis Colon Rectum, 2007, 50(2): 239-250.
|